comparemela.com

Latest Breaking News On - European medicines agency on - Page 1 : comparemela.com

Acurx Pharmaceuticals (ACXP) Granted FDA End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection

Acurx Pharmaceuticals (ACXP) Granted FDA End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states
Davidp-luci
Robertj-deluccia
Trial-oversight-committee
Acurx-pharmaceuticals-inc
Nasdaq
Data-monitoring-committee
Company-scientific-advisory-board
European-medicines-agency-on
Drug-administration
Acurx-pharmaceuticals

Novo to invest $6B to expand facilities | The Arkansas Democrat-Gazette

Novo Nordisk A/S will invest more than $6 billion to expand its manufacturing facilities as it fights to maintain dominance of a weight-loss market that s expected to hit $100 billion by 2030.

Denmark
Kalundborg
Sjæand
United-states
Copenhagen
Køavn
American
Americans
Robert-langreth
Fruergaard-jorgensen
Madison-muller
Eli-lilly

Mirati's KRAS-blocking cancer drug hits setback in Europe

The secrets of forever young 'superagers'

The secrets of forever young 'superagers'
euractiv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from euractiv.com Daily Mail and Mail on Sunday newspapers.

Madrid
Spain
Slovenia
Bucharest
Bucuresti
Romania
Ukraine
France
Paris
France-general
Las-palmas
Canarias

Eisai: Lecanemab Receives Priority Review Status In Japan For Alzheimer's Disease Treatment

WESTON (dpa-AFX) - Eisai Co., Ltd. and Biogen Inc. (BIIB) said that an application for manufacturing and marketing approval for an anti-amyloid-? (A?) protofibril antibody, lecanemab (generic name

China
Japan
Japanese
Eisai-co-ltd
Drug-administration-on
Japanese-ministry-of-health
European-medicines-agency-on
Devices-agency
Biogen-inc
More-such-health-news
Priority-review

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.